BAYER Pharmaceuticals has welcomed the decision by the Complaints Resolution Panel (CRP) that the Johnson & Johnson Zyrtec superiority claims were found to be misleading and in breach of sections of the Therapeutic Goods Advertising Code.
J&J's advertising had compared their hayfever product to Bayer's product, Claratyne, claiming that "Zyrtec starts to work faster than Claratyne".
The CRP determined this claim was "not verified, was not correct and balanced, was likely to arouse unwarranted expectations, was misleading, exploited the lack of knowledge of consumers and was a misleading comparison".
J&J has been ordered to withdraw the advertisement and any other representations that Zyrtec starts to work faster than Claratyne including from third parties, as well as providing evidence to the Panel of full compliance.
Details at www.tgacrp.com.au.
The above article was sent to subscribers in Pharmacy Daily's issue from 30 Sep 16
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 30 Sep 16
